Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Stereotactic ablative body radiation Clear all
Completed No phase listed Observational

Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy

NCT02449837
View directory record Official record
Conditions
Circulating Tumor Cells
Interventions
Blood draw
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 5, 2026, 5:22 AM EDT
Active, not recruiting Phase 1 Interventional

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT04073745
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Positive Surgical Margin, Resected Mass, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

NCT03148327
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab (MEDI 4736), Radiotherapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Spine, Prognostic Stage IV Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Stereotactic Body Radiotherapy, Surgery
Radiation · Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
153
States / cities
Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hormone Therapy, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT06130826
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional Results available

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

NCT04081688
View directory record Official record
Conditions
Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer

NCT03548285
View directory record Official record
Conditions
Glottic Carcinoma
Interventions
Radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

NCT03541850
View directory record Official record
Conditions
PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions
Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated No phase listed Observational

Bronchial Mapping (GCC 1635)

NCT02745548
View directory record Official record
Conditions
Thoracic Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Not listed Not applicable Interventional

CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer

NCT02070952
View directory record Official record
Conditions
Prostate Cancer
Interventions
CyberKnife Stereotactic Ablative Body Radiation Therapy
Radiation
Lead sponsor
Riverside Community Hospital, California
Other
Eligibility
18 Years and older · Male only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 1 Interventional

Adaptive Radiation for Abdominopelvic Metastases

NCT05880667
View directory record Official record
Conditions
Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Interventions
Adaptive Stereotactic Body Radiation
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

NCT04951115
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Etoposide, Durvalumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

NCT04021043
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity, Metastatic Malignant Solid Neoplasm
Interventions
Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

NCT07223307
View directory record Official record
Conditions
Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
Interventions
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

NCT02400814
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 5, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

NCT03126461
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
SAbR, Ipilimumab, Nivolumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

NCT03867175
View directory record Official record
Conditions
Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Stereotactic Body Radiation Therapy, Pembrolizumab
Radiation · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

NCT04936230
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Littleton, Colorado • Bloomington, Illinois • Canton, Illinois + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 5, 2026, 5:22 AM EDT
Terminated Not applicable Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

NCT01737151
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer
Interventions
stereotactic body radiation therapy, four fraction split-course SBRT
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 5, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00750269
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 5, 2026, 5:22 AM EDT